AMP German Cannabis Group Receives Import Licence for Medical Cannabis for imports from European Union Countries
BERLIN, Germany, March 9, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) announces that the Thuringian State Office for Consumer Protection or Thüringer Landesamt für Verbraucherschutz, (“TLV”) has granted an additional import licence for cannabis products for medical purposes from European countries to Germany in accordance to Paragraph §52a of the German Medicine Law or Arzneimittelgesetz to Alternative Medical Products GmbH (“AMP Germany”), a wholly-owned subsidiary of AMP.
TLV deals with fundamental matters of economic consumer protection and consumer policy for the Free State of Thuringia in Germany and grants the necessary licenses and permits for the import of medical cannabis into Germany to AMP.
With both the §52a and §72 licences from TLV, AMP can import and wholesale medical cannabis into the German pharmaceutical market with EU-GMP cannabis purchased from within and outside the European Union.
In addition, AMP anticipates receiving an irradiation permit to cover all possible medical cannabis production methods and completing the EU-GMP audit of its supply chain to guarantee a well-functioning supply chain to pharmacies and patients. Currently, all medical cannabis distributed in Germany is irradiated. The completion of the EU-GMP supply chain audit and irradiation permit are required to import from the Netherlands.
Dr. Stefan Feuerstein, Managing Director of AMP Germany, commented: “Being granted an additional licence for European Union imports [§52a AMG of the German Medicine Law] will allow AMP to begin importing from the Netherlands in early Q2 of 2020. Moreover, we expect our irradiation permit shortly, which is important in regard to our planned imports from the Netherlands and from Canada during Q3 of 2020.”